Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-12-07

Clinical Trial Update: Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) [Phase 2]

View source ↗

Summary

The Phase 2 study of GLPG1837 in cystic fibrosis patients with the G551D mutation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GLPG1837

Snippet

Sponsor: Galapagos NV | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED